Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015

Executive Summary

Agency's biosimilar meeting workload rose slightly; shifts in types of meetings may reflect maturation of individual biosimilar development programs.

You may also be interested in...



ANDA Pre-Submission Meetings A 'Challenge' To Integrate Into Development Timelines

US FDA officials appears worried about workload created by product development and pre-submission meetings for complex generics.

ANDA Pre-Submission Meetings A 'Challenge' To Integrate Into Development Timelines

US FDA officials appears worried about workload created by product development and pre-submission meetings for complex generics.

US FDA's Oncology Division Wants To Know About Your Pipeline, Not Just Your NDAs

Oncology Center of Excellence Director Richard Pazdur says agency invites sponsors to present about molecules under development to learn more about future plans.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS057591

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel